转化生长因子-β：癌症的一个治疗靶点。
Transforming growth factor-β: A therapeutic target for cancer.
作者信息
Haque Sulsal, Morris John C
机构信息
a Department of Internal Medicine , University of Cincinnati , Cincinnati , OH , USA.
b University of Cincinnati Cancer Institute , Cincinnati , OH , USA.
出版信息
Hum Vaccin Immunother. 2017 Aug 3;13(8):1741-1750. doi: 10.1080/21645515.2017.1327107. Epub 2017 Jun 2.
Abstract
Transforming growth factor-β (TGF-β) regulates cell growth and differentiation, apoptosis, cell motility, extracellular matrix production, angiogenesis, and cellular immunity. It has a paradoxical role in cancer. In the early stages it inhibits cellular transformation and prevents cancer progression. In later stages TGF-β plays a key role in promoting tumor progression through mainly 3 mechanisms: facilitating epithelial to mesenchymal transition, stimulating angiogenesis and inducing immunosuppression. As a result of its opposing tumor promoting and tumor suppressive abilities, TGF-β and its pathway has represented potential opportunities for drug development and several therapies targeting the TGF-β pathway have been identified. This review focuses on identifying the mechanisms through which TGF-β is involved in tumorigenesis and current therapeutics that are under development.
摘要
转化生长因子-β（TGF-β）调节细胞生长与分化、细胞凋亡、细胞迁移、细胞外基质生成、血管生成及细胞免疫。它在癌症中具有矛盾的作用。在早期，它抑制细胞转化并阻止癌症进展。在后期，TGF-β主要通过三种机制在促进肿瘤进展中起关键作用：促进上皮-间质转化、刺激血管生成和诱导免疫抑制。由于其具有相反的促肿瘤和抑肿瘤能力，TGF-β及其信号通路为药物开发提供了潜在机会，并且已经确定了几种靶向TGF-β信号通路的疗法。本综述着重于确定TGF-β参与肿瘤发生的机制以及目前正在研发的治疗方法。
相似文献
1
Transforming growth factor-β: A therapeutic target for cancer.转化生长因子-β：癌症的一个治疗靶点。
Hum Vaccin Immunother. 2017 Aug 3;13(8):1741-1750. doi: 10.1080/21645515.2017.1327107. Epub 2017 Jun 2.
2
TGF-beta signaling in cancer treatment.TGF-β 信号通路在癌症治疗中的作用。
Curr Pharm Des. 2014;20(17):2934-47. doi: 10.2174/13816128113199990591.
3
Transforming growth factor-beta: a target for cancer therapy.转化生长因子-β：癌症治疗的靶点。
J Immunotoxicol. 2010 Mar;7(1):15-26. doi: 10.3109/15476910903389920.
4
TGF-β Signaling in Cancer.癌症中的转化生长因子-β信号传导
J Cell Biochem. 2016 Jun;117(6):1279-87. doi: 10.1002/jcb.25496. Epub 2016 Feb 11.
5
Transforming growth factor β signaling pathway: A promising therapeutic target for cancer.转化生长因子β信号通路：癌症治疗的有前途靶点。
J Cell Physiol. 2020 Mar;235(3):1903-1914. doi: 10.1002/jcp.29108. Epub 2019 Jul 22.
6
Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression.靶向前列腺癌中的转化生长因子-β：肿瘤进展过程中的治疗可能性
Expert Opin Ther Targets. 2009 Feb;13(2):227-34. doi: 10.1517/14728220802705696.
7
Tgf-Beta pathway as a therapeutic target in bone metastases.TGF-β 通路作为骨转移治疗靶点。
Curr Pharm Des. 2010;16(11):1301-12. doi: 10.2174/138161210791034049.
8
TGF-β signaling in cancer.TGF-β 信号通路与癌症。
Acta Biochim Biophys Sin (Shanghai). 2018 Oct 1;50(10):941-949. doi: 10.1093/abbs/gmy092.
9
[TGF-β signaling pathways in cancers].癌症中的转化生长因子-β信号通路
Postepy Hig Med Dosw (Online). 2013 Sep 25;67:1008-17. doi: 10.5604/17322693.1068073.
10
Large- and small-molecule inhibitors of transforming growth factor-beta signaling.转化生长因子-β信号通路的大分子和小分子抑制剂
Curr Opin Investig Drugs. 2006 Jun;7(6):513-21.
引用本文的文献
1
A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs.用于纠正癌症驱动基因突变的碱基编辑平台揭示了保守的p53转录程序。
Genome Biol. 2025 Jul 22;26(1):217. doi: 10.1186/s13059-025-03667-7.
2
Multi-omics profiling of TGF-β isoforms and regulatory miRNAs in astrocytic tumors reveals TGF-β-3 as a prognostic biomarker.星形细胞瘤中转化生长因子-β（TGF-β）亚型和调控性微小RNA（miRNA）的多组学分析揭示TGF-β-3作为一种预后生物标志物。
Front Oncol. 2025 Jun 20;15:1592685. doi: 10.3389/fonc.2025.1592685. eCollection 2025.
3
Dynamics of inflammatory signals within the tumor microenvironment.肿瘤微环境中炎症信号的动态变化。
World J Exp Med. 2025 Jun 20;15(2):102285. doi: 10.5493/wjem.v15.i2.102285.
4
Anticancer potential of Thymoquinone from Nigella sativa L.: An in-silico and cytotoxicity study.黑种草中百里醌的抗癌潜力：一项计算机模拟和细胞毒性研究。
PLoS One. 2025 Jun 12;20(6):e0323804. doi: 10.1371/journal.pone.0323804. eCollection 2025.
5
Recent advances in therapeutic use of transforming growth factor-beta inhibitors in cancer and fibrosis.转化生长因子-β抑制剂在癌症和纤维化治疗应用中的最新进展。
Front Oncol. 2025 Apr 25;15:1489701. doi: 10.3389/fonc.2025.1489701. eCollection 2025.
6
Extracellular Matrix Stiffness: Mechanotransduction and Mechanobiological Response-Driven Strategies for Biomedical Applications Targeting Fibroblast Inflammation.细胞外基质硬度：针对成纤维细胞炎症的生物医学应用中机械转导与机械生物学响应驱动策略
Polymers (Basel). 2025 Mar 20;17(6):822. doi: 10.3390/polym17060822.
7
A New Histology-Based Prognostic Index for Acute Myeloid Leukemia: Preliminary Results for the "AML Urayasu Classification".一种基于组织学的急性髓系白血病新预后指数：“AML 浦安分类”的初步结果
J Clin Med. 2025 Mar 15;14(6):1989. doi: 10.3390/jcm14061989.
8
The CD39/CD73/Adenosine and NAD/CD38/CD203a/CD73 Axis in Cutaneous T-Cell Lymphomas.皮肤T细胞淋巴瘤中的CD39/CD73/腺苷与NAD/CD38/CD203a/CD73轴
Cells. 2025 Feb 19;14(4):309. doi: 10.3390/cells14040309.
9
Targeting transforming growth factor-β1 by methylseleninic acid/seleno-L-methionine in clear cell renal cell carcinoma: Mechanisms and therapeutic potential.甲基亚硒酸/硒代-L-蛋氨酸靶向转化生长因子-β1在肾透明细胞癌中的作用机制及治疗潜力
Cancer Treat Res Commun. 2024;42:100864. doi: 10.1016/j.ctarc.2025.100864. Epub 2025 Jan 9.
10
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.利用肿瘤微环境：通过调节上皮-间质转化实现靶向癌症治疗
J Hematol Oncol. 2025 Jan 13;18(1):6. doi: 10.1186/s13045-024-01634-6.
本文引用的文献
1
ATRA modulates mechanical activation of TGF-β by pancreatic stellate cells.全反式维甲酸调节胰腺星状细胞对转化生长因子-β的机械激活作用。
Sci Rep. 2016 Jul 4;6:27639. doi: 10.1038/srep27639.
2
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.TGF-β受体I激酶抑制剂加芦尼替尼在日本晚期实体瘤患者中的1期研究。
Cancer Chemother Pharmacol. 2015 Dec;76(6):1143-52. doi: 10.1007/s00280-015-2895-4. Epub 2015 Nov 3.
3
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.转化生长因子-β信号通路小分子抑制剂加鲁尼西替（LY2157299一水合物）的临床开发
Drug Des Devel Ther. 2015 Aug 10;9:4479-99. doi: 10.2147/DDDT.S86621. eCollection 2015.
4
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.贝伐珠单抗联合化疗用于治疗晚期非小细胞肺癌的随机、双盲、安慰剂对照Ⅲ期研究
培美曲塞联合顺铂或卡铂用于初治晚期非鳞状非小细胞肺癌的随机、双盲、安慰剂对照Ⅲ期研究
Eur J Cancer. 2015 Nov;51(16):2321-9. doi: 10.1016/j.ejca.2015.07.035. Epub 2015 Aug 14.
5
Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.转化生长因子-β受体激酶抑制剂加鲁尼西替（一水合LY2157299）在患者来源肿瘤异种移植物中的抗肿瘤活性
Cell Oncol (Dordr). 2015 Apr;38(2):131-44. doi: 10.1007/s13402-014-0210-8. Epub 2015 Jan 9.
6
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.转化生长因子-β受体I激酶抑制剂加芦尼替尼在晚期癌症患者1期研究中的药代动力学、药效学及生物标志物评估
Invest New Drugs. 2015 Apr;33(2):357-70. doi: 10.1007/s10637-014-0192-4. Epub 2014 Dec 23.
7
An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.一种新型 TGF-β 型 I 受体抑制剂 IN-1130 通过抑制上皮-间充质转化阻断乳腺癌肺转移。
Cancer Lett. 2014 Aug 28;351(1):72-80. doi: 10.1016/j.canlet.2014.05.006. Epub 2014 Jun 2.
8
Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.基于药代动力学/药效学模型确定新型转化生长因子-β抑制剂一水合LY2157299的治疗窗。
Br J Clin Pharmacol. 2014 May;77(5):796-807. doi: 10.1111/bcp.12256.
9
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.GC1008（氟索利单抗）的I期研究：一种用于晚期恶性黑色素瘤或肾细胞癌患者的人抗转化生长因子-β（TGFβ）单克隆抗体。
PLoS One. 2014 Mar 11;9(3):e90353. doi: 10.1371/journal.pone.0090353. eCollection 2014.
10
Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer.在乳腺癌小鼠模型中，使用抗 TGFβ 抗体和环磷酰胺进行有效的化疗免疫治疗。
PLoS One. 2014 Jan 9;9(1):e85398. doi: 10.1371/journal.pone.0085398. eCollection 2014.
Zotero 插件